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Abstract
Background: Lung cancer is a common cause of cancer-related death. Staging typically includes positron emission
tomography (PET) scanning, in which
18F-fluoro-2-dexoy-D-glucose (FDG) is taken up by cells proportional to
metabolic activity, thus aiding in differentiating benign and malignant pulmonary nodules. Uptake of FDG can also
occur in the abdomen. The clinical significance of incidental intraabdominal FDG uptake in the setting of
pulmonary nodules is not well established. Our objective was to report on the clinical significance of incidental
intra-abdominal FDG activity in the setting of lung cancer.
Methods: Fifteen hundred FDG-PET reports for studies performed for lung cancer were retrospectively reviewed
for the presence of incidental FDG-positive intraabdominal findings. Patient charts with positive findings were then
reviewed and information extracted.
Results: Twenty-five patients (25/1500) demonstrated incidental intraabdominal FDG uptake thought to be
significant (1.7%) with a mean patient age of 71 years. Colonic uptake was most common (n = 17) with 9 (52%)
being investigated further. Of these 9 cases, a diagnosis of malignancy was made in 3 patients, pre-malignant
adenomas in 2 patients, a benign lipoma in 1 patient and no abnormal findings in the remaining patients. 8
patients were not investigated further (3 diagnosed with metastatic lung cancer and 2 were of advanced age)
secondary to poor prognosis.
Conclusion: Incidental abdominal findings in the colon on FDG-PET scan for work-up of pulmonary nodules need
to be further investigated by colonoscopy.
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Background
Lung cancer is the most common cause of cancer-related
deaths worldwide. Staging typically uses imaging techni-
ques such as chest radiography, computed tomography
(CT), and occasionally magnetic resonance imaging
(MRI). In the last decade, use of positron emission tomo-
graphy (PET) has been increasingly employed to improve
both the staging of lung cancer and the assessment of
patients with pulmonary nodules (Figure 1) [1-3]. Cells in
a malignant tumor undergo glycolysis at an increased
rate, and hence have greater cellular uptake of glucose
[4].
18F-fluoro-2-dexoy-D-glucose (FDG) is a glucose
analog that undergoes the same mechanism of uptake as
glucose but becomes trapped within the tumor cell. FDG
emits a positron, which can ultimately be imaged making
it a good tracer for metabolic activity [5,6]. Uptake of
FDG can also occur in other cells within the body, lead-
ing to incidental extra-thoracic findings in this setting
[1]. Incidental foci of FDG uptake may include striated
muscle, inflammation, thrombosis and second primary
malignancies [1,7,8]. These incidental primary malignan-
cies may include colon cancer, which has risk factors in
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smoking [9].
Previous studies have assessed the efficacy of PET for
lung cancer staging and have reported incidental extra-
thoracic findings. The clinical significance of incidental
FDG uptake within the abdomen in asymptomatic
patients remains unclear. Our objective is to review the
experience at our institution and to evaluate the clinical
significance of incidental intra-abdominal findings on
FDG-PET scans performed for staging of lung cancer or
the assessment of pulmonary nodules.
Methods
Ethics approval was obtained from the Health Research
Ethics Board at the University of Alberta prior to com-
mencement of this project.
Patient Population
A report database of FDG-PET scans performed between
October 2002 and April 2008 at the major regional cancer
center (Cross Cancer Institute, Edmonton, Alberta), was
initially filtered according to indication and we selected
out scans performed for ‘investigation of pulmonary
nodules’. This captured 1500 FDG-PET scan reports
performed for evaluation of pulmonary nodules as part of
staging for lung cancer or assessment of malignant poten-
tial. The 1500 FDG-PET scans were then reviewed for pre-
sence of incidental FDG-positive intraabdominal findings.
Incidental intraabdominal FDG-uptake was defined as
“focal” and intense uptake compared to background activ-
ity as observed by the nuclear medicine physicians. There
was no specific maximum standardized uptake value
(SUVmax) to define incidental focal uptake. However, a
number of experienced nuclear medicine physicians inter-
preted the FDG-PET scans and based on their interpreta-
tion reported significant intraabdominal FDG-uptake. PET
imaging reports indicating focal FDG-uptake in the abdo-
men were assumed to be abnormal. Patients with prior
computed tomographic (CT) or magnetic resonance ima-
ging indicating extra-thoracic disease were excluded. Also,
patients with known diagnoses of intra-abdominal malig-
nancy were excluded. Patient charts with incidental
intraabdominal findings were then retrospectively
reviewed and the following data was extracted: patient
information including demographics, risk factors, type and
clinical stage of lung cancer, and treatment. In patients
with FDG-positive lung and abdominal findings, informa-
tion on investigations of incidental abdominal findings,
diagnosis and treatment were extracted.
FDG-PET Protocol
At our Regional Cancer Center (standard whole body
FDG protocols from the skull base to the proximal thighs
were used. PET scans were obtained using a dedicated
PET (Philips Allegro, Best, the Netherlands) or PET/CT
scanner (Philips Gemini, Best, the Netherlands). Patients
fasted for a minimum of 6 h before FDG injection. FDG
was administered at a dose of 5.2 MBq/kg ± 10% intrave-
nously with a maximum dose of 740 MBq. PET images
were acquired at 3 to 4 minutes per bed position. For
PET studies attenuation correction was performed using
a
137Cs transmission source. For PET/CT studies, CT
Figure 1 Fused coronal, sagittal and transaxial FDG PET/CT images in an 84 year old male (Patient 11). The cross-hairs localize an FDG-
avid lung cancer.
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structed using an ordered-subset expectation maximiza-
tion iterative reconstruction algorithm.
Results
A total of 1500 FDG-PET scans were reviewed, with 25
demonstrating incidental intraabdominal findings (1.7%)
(Figure 2). As seen in Table 1, the mean age of patients
with incidental intraabdominal findings was 71 years
(range: 30 to 89 years of age), with 52% females. The most
common location within the abdomen for focal FDG
uptake was the colon (n = 17), followed by the rectal or
anorectal junction (n = 4). Of the 17 cases with incidental
colonic findings, 9 (52%) were investigated further with
either contrast-enhanced CT abdominal scan or colono-
scopy. None of the four cases with rectal/anorectal find-
ings were investigated. Of the nine colonic cases, a
diagnosis of malignancy was made in three patients, pre-
malignant adenomas in two patients (Figure 3), a benign
lipoma in one patient and no abnormal findings in the
remaining patients (Table 2). Of the eight patients with
focal colonic FDG uptake not investigated further, three
patients (patients 3, 4, and 6) had metastatic lung cancer
and two patients (patients 14 and 15) were of advanced
age. For the other three patients with focal colonic FDG
uptake, chart review indicates that no further investiga-
tions were performed. Further details of investigations per-
formed for colonic incidental findings are given in Table 2.
A patient with incidental FDG uptake in the pancreas
was diagnosed with an insulinoma and received surgical
resection by pancreaticoduodenectomy. A patient with
incidental FDG uptake in the abdominal wall, was found
to have no remarkable findings on abdominal ultra-
sound. Two patients with FDG uptake in the diaphragm
and bladder were not investigated further according to
medical records.
Discussion
Our retrospective review demonstrates that incidental
FDG positive intraabdominal findings on PET imaging
for lung cancer may represent clinically significant
pathology, especially if the lesion is located in the colon.
Of the nine patients investigated for incidental FDG
uptake within the colon, three (33%) were ultimately
found to have colon cancer, with two others (22%) having
pre-malignant lesions (adenomas). Pre-malignant lesions
Figure 2 Flow diagram of reviewed FDG-PET scans (Abdo = abdominal; jxn = junction).
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PET Scan
Pt Age (yrs) Sex Lung FDG+ ABDO FDG+ ABDO FDG+ PET site Pulmonary Diagnosis ABDO Findings Invest Abdominal Diagnosis
1 71 M + + Colon N/A Yes Lipoma
2 64 M + + Colon NSCLC Yes Normal
3 79 M + + Colon Metastatic NSCLC No -
4 63 F + + Colon Metastatic NSCLC No -
5 84 F + + Right Colon Adenocarcinoma No -
6 81 F + + Right Colon Metastatic NSCLC No -
7 64 F + + Right Colon Bronchoalveolar cancer Yes Normal
8 67 F + + Right colon SCC Yes Normal
9 74 F + + Transverse Colon Metastasis from Colon Cancer Yes Colon Adenocarcinoma
10 82 M + + Left colon Bronchogenic cancer Yes Colon Adenocarcinoma
11* 84 M + + Left Colon NSCLC Yes Colon Adenocarcinoma
12 80 M - + Sigmoid Colon Benign No -
13 75 M + + Sigmoid Colon Benign Yes Adenoma
14 89 F + + Sigmoid Colon Bronchogenic cancer No -
15 88 F - + Sigmoid Colon Benign No -
16 77 M + + Sigmoid Colon SCC No -
17 77 M - + Rectosigmoid Benign Yes Adenoma
18 30 M + + Rectum Reactive Lymphoid Hyperplasia No -
19 54 M + + Anorectal junction Spindle cell Cancer No -
20 78 F + + Anorectal junction NSCLC No -
21* 64 F + + Anorectal junction NSCLC No -
22 65 F + + Diaphragm Adenocarcinoma No -
23 74 F + + Bladder NSCLC No -
24 54 M + + Pancreas Benign Yes Islet Cell Tumor
25 49 F + + ABDO wall N/A Yes Normal
Mean 71 52% F





























































































7such as colonic adenomas have been previously reported
to accumulate FDG on PET imaging [10].
Zhuang et al retrospectively assessed the records of
500 patients evaluated by FDG-PET imaging for pul-
monary nodules at their institution and found that 17
had colonic uptake with 5 (35%) proven colon cancers
[11]. Beatty et al reported similar findings, in which
PET/CT imaging was performed on over 2000 cancer
patients [12]. Of the 133 patients investigated for inci-
dental findings on PET/CT imaging, 31% were found to
have a second primary malignancy [12]. Interestingly,
PET imaging has been shown to be highly sensitive for
intra-luminal colon cancer. In a study by Abdel-Nabi
et al, PET imaging assessed 37 patients with known
colon cancer and all carcinomas were identified (sensi-
tivity, 100%) [13]. These authors estimated a positive
predictive value of 90% [13]. Contrastingly, Weston et al
reported a positive predictive value closer to 65% [14].
This discrepancy may be related to the sensitivity of
PET imaging being influenced by both size and histol-
ogy of the colonic lesion [14].
One of the advantages of staging cancer patients with
PET imaging is the ability to detect not only occult
metastatic disease but also synchronous malignancies.
Age remains the most significant risk factor for colorec-
tal cancer [15], and as seen in our review, most patients
Figure 3 Fused coronal, sagittal and transaxial FDG PET/CT images in an 84 year old patient (Patient 11). The cross-hairs localize intense
uptake in the left colon.
Table 2 Diagnosis and Treatment of Incidental Colonic Findings
Pt ABDO FDG+ PET site SUVmax Investigations Intraabdominal Diagnosis Treatment Final Pathology
1 Colon 4.1 Colonoscopy Lipoma in colon Endoscopic Polypectomy Lipoma
2 Colon 5.7 Colonoscopy Normal - Normal
7 Right Colon 3.8 Colonoscopy Normal - Normal
8 Right colon 9.5 CT Abdomen Normal - Normal
9 Transverse Colon 5.3 CT Abdomen Metastatic Colon Cancer Right Hemicolectomy Metastatic Colon Adenocarcinoma
10 Left colon 6.1 Colonoscopy Villous Adenoma Left Hemicolectomy Colon Adenocarcinoma
11 Left Colon 8.8 Colonoscopy Colon Cancer Endoscopic Polypectomy Colon Adenocarcinoma
13 Sigmoid Colon N/A Colonoscopy Tubulovillous Adenoma Endoscopic Polypectomy Adenoma
17 Rectosigmoid Colon 12.8 Endoscopy Villous Adenoma Endoscopic Polypectomy Adenoma
24 Pancreas 6.1 CT Abdomen Endocrine tumor Whipple’s Procedure Islet Cell Tumor
25 ABDO wall 1.5 US Abdomen Normal - Normal
ABDO = abdominal; FDG = fluorodeoxyglucose; + = positive; US = ultrasound; CT = computed tomography; SUVmax = maximum standardized uptake value; N/A
= not available
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icant risk factor for lung cancer remains smoking.
According to a review by Giovannucci, tobacco is
strongly associated with colon cancer and tobacco use is
associated with a 2-3 fold increased risk of colorectal
adenoma. These authors speculate that smoking may be
the potential source of up to one in five colorectal can-
cers [9].
There are several limitations to this study. The main
limitation of this study is the retrospective nature. Second,
of the 1500 PET scans performed at our institution, we
were unable to filter the results to isolate those performed
for lung cancer staging and those for investigation of pul-
monary nodules. Third, there were a number of patients
either lost to follow-up or who may have been investigated
without appropriate documentation. These factors can
lead to sample bias, however correlation of our results
with other studies is supportive. Furthermore, since only
PET scans with positive FDG uptake were reviewed
further; we cannot comment on false-negative rates of
PET scan. One final limitation of this study is that there
were a mixture of PET only and PET/CT imaging studies
performed. The CT component may provide additional
information potentially improving the anatomic localiza-
tion and specificity of the PET findings, although this is
controversial [16]. Modern standard-of-care is to perform
PET/CT for all patients being investigated for pulmonary
nodules or being staged for lung cancer.
As lung cancer continues to be the most common
cause of cancer-related death in North America, PET
imaging will be increasingly used to evaluate pulmonary
nodules. The frequency of incidental findings of focal
hypermetabolism can be expected to increase and clini-
cians will be faced with the decision of how best to inves-
tigate these patients, if at all. With the majority of these
findings representing malignant or premalignant neo-
plasm [17], they can be classified as clinically significant
despite lack of symptomatology. Our study found that
the majority (56%) of cases with incidental colonic FDG
uptake had an underlying diagnosis of malignant or pre-
malignant lesions in the colon. This is contrary to our
findings of FDG uptake in the head and neck region, in
which there was a low incidence of malignancy (unpub-
lished data). Evaluation of incidental focal colonic FDG
uptake with colonoscopy and biopsy is recommended, as
colonic pathology is often undetectable by ultrasound,
CT scanning and MRI. Review of the PET imaging with
the endoscopist may also lead to better localization of the
lesion [17]. Treatment plans will continue to be indivi-
dualized based on the primary pulmonary diagnosis.
Further prospective studies are needed to define clear cri-
teria for further investigation of potentially significant
incidental intraabdominal FDG-positive findings.
Conclusion
In conclusion, FDG-positive incidental intraabdominal
findings on PET imaging during work-up of pulmonary
nodules, may represent clinically significant pathology,
especially if localized to the colon. Further investigation
with colonoscopy is recommended.
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